Generation Bio

Generation Bio

  • Founded: 2017
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: Hemophilia A
  • Drug types: GEN, HEM, OPH, GER, VAC, HEP, PED
  • Lead product: Undisclosed
  • Product link:
  • Funding: $230M IPO Jun 2020; $110M C Jan 2020; $100M B Feb 2018; $25M A Jan 2018

job board

Short description:

Gene Therapy

Drug notes:

7 undisclosed programs RD PKU, Wilson disease, Gaucher disease, Leber congenital amaurosis 10, Stargardt disease, wet AMD, ETAP

Long description:

Generation Bio is developing a new class of genetic medicines. Using their proprietary non-viral genetic medicine platform, Generation Bio is creating scalable and redosable medicines. The platform uses closed-ended DNA (ceDNA) encased in cell-targeted lipid nanoparticles. ceDNA has 3x the carrying capacity of AAV capsids and has the potential to offer durable expression. The medicines designed by Generation Bio are efficiently manufactured - ceDNA can be consistently produced with high purity using their cell-free rapid enzymatic synthesis approach. Generation Bio is building a portfolio initially targeting diseases of the liver and retina before expanding into skeletal muscle and the CNS.


Generation Bio
(Senior) Counsel, Corporate & Transactions
Cambridge, MA|8 days ago
Generation Bio
Associate Scientist / Senior Associate Scientist, ...
Cambridge, MA|9 days ago
Generation Bio
Senior Scientist, Medicinal Chemistry
Cambridge, MA|51 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy